合作方面， bit.bio是合成生物巨头 Ginkgo Bioworks 的首批合作伙伴，其ioCells将被整合至Ginkgo的技术网络中；还与基因编辑龙头 Synthego合作 构建人类细胞基因工程用于细胞治疗的平台。

英格兰剑桥--(BUSINESS WIRE)--(美国商业资讯)--今天，bit.bio董事会迎来了三位新成员，他们在将世界一流科学导入新行业并促进公司发展方面均拥有丰富经验。新董事将在bit.bio扩展其专有的合成生物学细胞编程技术平台过程中提供重要指导，帮助创建基于人体细胞的 ...

bit.bio ...

Dr Hermann Hauser, serial entrepreneur, co-founder of Amadeus Capital Partners and founder of semiconductor company, Arm Ltd, and gene-sequencing company, Solexa / Illumina, joins as chair of the ...

Synthego to develop multiplexed and complex genetic engineering strategies, increasing the safety and speed at which bit.bio can engineer human cells for cell therapies. bit.bio aims to leverage ...

M&G Investments (M&G) today announces that it has led a US$50 million Series C funding round for bit.bio, the Cambridge-based biotech company pioneering next-generation human cell programming ...

The Ginkgo Technology Network brings together over 25 diverse partners across an array of capabilities including AI, genetic medicines, biologics, and manufacturing. As a Ginkgo Technology Network ...

The report provides evidence-based metrics aligned with the UN Sustainable Development Goals (SDGs), highlighting year-over-year improvements. It demonstrates how sustainability is integrated across ...

CAMBRIDGE, England, Dec. 2, 2025 /PRNewswire/ -- bit.b io, the global leader in cell programming technology, today announces the publication of its 2025 Corporate Sustainability Report, reaffirming ...

Cambridge-based pioneer in nextgen human cell programming, has raised $50 million Series C cash in a round led by M&G ...

Automata, a leading robotics and automation company powering life sciences labs, today announced it is partnering with bit.bio, to automate a key aspect of the manufacturing process of their iPSC ...